The strategic investment is likely to play a key role in increasing the scale of Neuberg and help the company get ready for its upcoming IPO
Kotak Strategic Situations India Fund II, managed by Kotak Alternate Asset Managers, announced an investment of Rs 940 crore in Neuberg Diagnostics to support Neuberg’s inorganic expansion strategy.
Rahul Shah, Partner, Kotak Alt said, “We are excited to partner with Neuberg as they work to transform the diagnostics landscape in India. The investment reflects our confidence in Neuberg's vision and potential. We are confident that this strategic investment will play a key role in increasing the scale of Neuberg and help the company get ready for its upcoming IPO. This investment solidifies our commitment to supporting quality healthcare solutions that improve patient outcomes and accessibility.”
Dr GSK Velu, Founder and MD, Neuberg, said, “The funding will enable us to enhance our capabilities in the areas of personalised medicine, integrated diagnostics and inorganically expand our footprint across the country. As we prepare for an IPO, we remain committed to making high-quality diagnostics accessible to all, ensuring that our services continue to meet the evolving needs of clinicians and patients.”